Long-term safety of tacrolimus ointment in children treated for atopic dermatitis

Expert Opinion on Drug Safety

Volumn 2, Issue 5, 2003, Pages 457-465

  Shainhouse, Tsippora ^a   Eichenfield, Lawrence F ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

atopic dermatitis (AD); efficacy; long term; safety; tacrolimus; topical; topical immunomodulators

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CHILD; DRUG ADMINISTRATION; ECONOMICS; ENZYMOLOGY; HEALTH CARE COST; HUMAN; INTRADERMAL DRUG ADMINISTRATION; OINTMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

ADMINISTRATION, CUTANEOUS; CHILD; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; TACROLIMUS;

EID: 2142738797     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.5.457     Document Type: Review

References (75)

1. BOHME M, SVENSSON A, KULL I, WAHLGREN CF: Hanifin's and Rajka's minor criteria for atopic dermatitis: which do 2-year-olds exhibit? JAAD (2000) 43:785-792.
2. HANIFIN JM, RAJKA G: Diagnostic features of atopic eczema. Acta Derm. Venereol. Suppl. (Stockholm) (1980) 92:44-47.
3. WILLIAMS H: Disease definition and measures of disease frequency. JAAD (2001) 45:S33-S36. (Pubitemid 32661823)
4. NIMMAGADDA SR, EVANS R: Allergy: etiology and epidemiology. Pediatr. Rev. (1999) 20(4):111-115.
5. LAUGHTER D, ISTVAN JA, TOFTE SJ, HANIFIN JM: The prevalence of atopic dermatitis in Oregon schoolchildren. JAAD (2000) 43:649-55.
6. LARSEN FS, HANIFIN JM: Epidemiology of atopic dermatitis. Immunol. Allergy Clin. North Am. (2002) 22(1):1-24. (Pubitemid 34137417)
7. LAPIDUS CS: Role of social factors in atopic dermatitis: the US perspective. JAAD (2001) 45:S41-S43. (Pubitemid 32661825)
8. LAPIDUS CS, SCHWARTZ DF, HONIG PJ: Atopic dermatitis in children: who cares? Who pays? JAAD (1993) 28:699-703. (Pubitemid 23133378)
9. ELLIS CN, DRAKE LA, PRENDERGAST MM et al.: Cost of atopic dermatitis and eczema in the United States. JAAD (2002) 46(3):361-370. (Pubitemid 34225399)
10. SU JC, KEMP AS, VARIGOS GA, NOLAN TM: Atopic eczema: its impact on the family and financial cost. Arch. Dis. Child. (1997) 76:159-162. (Pubitemid 27086890)
11. PALLER A, MCALLISTER R, DOYLE J et al.: Atopic dermatitis in pediatric patients: perceptions of physicians and parents. Presented at the American Academy of Dermatology Annual Meeting, San Francisco (2000).
12. BERNARD LA, EICHENFIELD LF: Topical immunomodulators for atopic dermatitis. Curr. Opin. Pediatr. (2002) 14:414-418. (Pubitemid 34774926)
13. BOGUNIEWICZ M, LEUNG DYM: Pathophysiologic mechanisms in atopic dermatitis. Semin. Cutan. Med. Surg. (2001) 20(4):217-225. (Pubitemid 33139088)
14. BEIBER T: New insights in the structure and biology of the high affinity receptor for IgE (Fc?RI) on human epidermal Langerhans cells. J. Dermatol. Sci. (1996) 13(1):71-75.
15. WOLLENBERG A: Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J. Invest. Dermatol. (1996) 106(3):446-453. (Pubitemid 26117582)
16. JURGENS M: Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc?RI. J. Immunol. (1995) 155(11):5184-5189.
17. JUDGE MR, MORGAN G, HARPER JI: A clinical and immunological study of Netherton's syndrome. Br. J. Dermatol. (1994) 131:615-621. (Pubitemid 24344044)
18. HERSHEY GK, FRIEDRICH MF, ESSWEIN LA et al.: The association of atopy with a gain-of-function mutation in the subunit of the interleukin-4 receptor. N. Engl. J. Med. (1997) 337:1720-1725. (Pubitemid 27527768)
19. COOKSON W, HARPER JI, MOFFATT MF: Genetics of atopic dermatitis. Immunol. Allergy Clin. North Am. (2002) 22(2):199.
20. LEUNG DYM: Pathogenesis of atopic dermatitis. J. Allergy Clin. Immunol. (1999) 104(3 Pt 2):S99-S108.
21. MORISHITA Y, TADA J, SATO A et al.: Possible influences of Staphylococcus aureus on atopic dermatitis-the colonizing features and the effects of staphylococcal enterotoxins. Clin. Exp. Allergy (1999) 29:1110-1117. (Pubitemid 29359430)
22. LEUNG DYM: Immunopathogenesis of atopic dermatitis. Immunol. Allergy Clin. North. Am. (2002) 22(1):73-90. (Pubitemid 34137421)
23. LEUNG DYM: Atopic dermatitis and the immune system: the role of superantigens and bacteria. JAAD (2001) 45(1):S13-S16. (Pubitemid 32661818)
24. SOWDEN JM, BERTH-JONES J, ROSS JS et al.: Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet (1991) 338:137-140.
25. ATAKAN N, ERDEM C: The efficacy, tolerability and safety of a new oral formulation of Sandimmune-Neoral in severe refractory atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. (1998) 11:240-246. (Pubitemid 29010430)
26. REITAMO S, VAN LEENT EJM, HO V et al.: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J. Allergy Clin. Immunol. (2002) 109(3):547-555. (Pubitemid 34234209)
27. TOCCI MJ: The immunosuppressant FK506 selectivity inhibits expression of early T cell activation genes. J. Immunol. (1989) 143(2):718-726. (Pubitemid 19191575)
28. PANHANS-GROS A, NOVAK N, KRAFT S, BEIBER T: Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J. Allergy Clin. Immunol. (2001) 107(2):345-352. (Pubitemid 32173914)
29. WOLLENBERG A, SHARMA S, VON BUBNOFF et al.: Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J. Allergy Clin. Immunol. (2001) 107(3):519-525. (Pubitemid 32210034)
30. BORNHOVD E, BURGDORF WHC, WOLLENBERG A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol. (2001) 45(5):736-743. (Pubitemid 33032572)
31. REMITZ A: Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J. Allergy Clin. Immunol. (2001) 107(1):196-197. (Pubitemid 32105267)
32. HAUK PJ, WENZEL SE, TRUMBLE AE et al.: Increased T cell receptor (TCR)-BV8+ T cells in bronchoalveolar lavage of poorly controlled asthmatics: a potential role for microbial superantigens. J. Allergy Clin. Immunol. (1998) 101:977A.
33. NGHEIM P, PEARSON G, LANGLEY RG: Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol. (2002) 46:228-241. (Pubitemid 34118380)
34. RUZICKA T, BIEBER T, SCHOPF E et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. N. Engl. J. Med. (1997) 337:816-821. (Pubitemid 27391631)
35. BOGUNIEWICZ M, FIEDLER VC, RAIMER S et al.: A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J. Allergy Clin. Immunol. (1998) 102:637-644.
36. HANIFIN J, LING M, LANGLEY R et al.: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I: efficacy. JAAD (2001) 44(Suppl):S28-S57.
37. SOTER NA, FLEISCHER AB, WEBSTER GF et al.: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part II: safety. JAAD (2001) 44:S39-S46. (Pubitemid 32047912)
38. PALLER A, EICHENFIELD LF, LEUNG D et al.: A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. JAAD (2001) 44:S47-S57. (Pubitemid 32049029)
39. REITAMO S, WOLLENBERG A, SCHOPF E et al.: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch. Dermatol. (2000) 136:999-1006. (Pubitemid 30629127)
40. KAWASHIMA M: FK506 Ointment Study Group: long-term treatment with FK506 (tacrolimus) ointment in patients with atopic dermatitis: analysis at the time of 2-year observation. Rinsho Iyako (2001) 17:705-726.
41. KANG S, LUCKY A, PARISER D et al.: Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. JAAD (2001) 44(Suppl):S58-S64. (Pubitemid 32047913)
42. ROBINSON N, SINGRI P, GORDON KB: Safety of the new macrolide immunomodulators. Semin. Cutan. Med. Surg. (2001) 20(4):242-249. (Pubitemid 33139091)
43. PIRSCH JD, MILLER J, DEIERHOI MH et al.: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 63:977-983. (Pubitemid 27173021)
44. FINN WF: FK506 nephrotoxicity. Ren. Fail. (1999) 21:319-329. (Pubitemid 29318198)
45. RUIZ P, KOLBECK PC, SCOGGS MW et al.: Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation (1988) 45:91.
46. HUNTRESS JD, PAPADAKOS PJ: The role of calcium-channel antagonists in solid organ transplantation. New Horiz. (1996) 4:129-133. (Pubitemid 26109258)
47. FRANK B, PERDRIZET GA, WHITE HM et al.: Neurotoxicity of FK506 in liver transplant recipients. Transplant. Proc. (1993) 25:1887-1888. (Pubitemid 23125135)
48. FREZZA EE, FUNG JJ, VAN THIEL DH: Non-lymphoid cancer after liver transplantation. Hepatogastroenterology (1997) 44:1172-1181. (Pubitemid 27326179)
49. JAIN AB, YEE LD, NALESNIK MA et al.: Comparative incidence of de novo non-lymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 66:1193-1200. (Pubitemid 28530324)
50. RADOMSKI JS, MORITZ MJ, MUNOZ SJ et al.: National Transplantation Pregnancy Registry: analysis of pregnancy outcomes in female liver transplant recipients. Liver Transplant Surg. (1995) 1:281-284.
51. BOS JD, WITKAMP L, ZONNERALD IM et al.: Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK506 multi-centre Psoriasis Study Group. Arch. Dermatol. (1996) 132:419-423.
52. ALAITI S, KANG S, FIEDLER VC et al.: Tacrolimus (FK506) ointment for atopic dermatitis: a Phase I study in adults and children. JAAD (1998) 38:69-76. (Pubitemid 28100468)
53. OIKARINEN A, AUTIO P: New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin. Exp. Dermatol. (1991) 16:416-419.
54. REITAMO S: Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J. Invest. Dermatol. (1998) 111(3):396-398. (Pubitemid 28400083)
55. FLEISCHER, AB, LING M, EICHENFIELD L et al.: Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. JAAD (2002) 47:562-570.
56. KOO JYM, PROSE N, FLEISCHER A, RICO MJ: Safety and efficacy of tacrolimus ointment monotherapy in over 7,900 atopic dermatitis patients: results of an open-label study. Ann. Dermatol. Venereol. (2002) 129:1S414, P0244. Abstract.
57. PALLER A, CARO I, WEINSTEIN G, RICO MJ: Long-term safety and efficacy of tacrolimus ointment monotherapy in atopic dermatitis patients: open-label study results. Ann. Dermatol. Venereol. (2002) 129:1S247, IC1245. Abstract.
58. REMITZ A, REITAMO S, ERKKO P et al.: Tacrolimus ointment improves psoriasis in a microplaque assay. Br. J. Dermatol. (1999) 141:103-107. (Pubitemid 29333700)
59. LAUERMA A, MAIBACH H, GRANLUND H et al.: Inhibition of allergic contact reactions by topical FK506. Lancet (1992) 340:556.
60. MCELWEE KJ, RUSHTON DH, TRACHY R et al.: Topical FK506: a potent immunotherapy for alopecia areata? Studies using the experimental bald rat model. Br. J. Dermatol. (1997) 137:491-497. (Pubitemid 27469497)
61. YAMAMOTO S, JIANG H, KATO R: Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J. Invest. Dermatol. (1994) 102:160-164. (Pubitemid 24060402)
62. SCHUPPE H, HOMEY B, ASSMANN T et al.: Topical tacrolimus for pyoderma gangrenosum. Lancet (1998) 351:832.
63. VENTE C: Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br. J. Dermatol. (1999) 140(2):338-342. (Pubitemid 29111368)
64. CASSON D, ELTUMI M, TOMLIN S et al.: Topical tacrolimus may be effective in the treatment of oral and perianal Crohn's disease. Gut (2000) 47:436-440.
65. ALLEN A, SIEGFRIED E, SILVERMAN R et al.: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. (2001) 137:747-750. (Pubitemid 32577856)
66. WAHN U, PARISER D, GOTTLIEB AB et al.: Low blood concentrations of SDZ ASM-981 in infants with extensive atopic dermatitis treated with cream 1%. Abstract presented at 59th Annual Meeting of the American Academy of Dermatology, Washington DC, March 2-7 (2001).
67. EICHENFIELD L, LUCKY A, BOGUNIEWICZ M et al.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. JAAD (2002) 46:495-504.
68. PAPP K, HO V, HALBERT A et al.: Pimecrolimus (Elidel, SDZ ASM-981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis. Proceedings of the World Congress of Pediatric Dermatology, Cancun, Mexico, May 2001. Abstract.
69. KAPP A, PAPP K, BINGHAM A et al.: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J. Allergy Clin. Immunol. (2002) 110(2):277-284.
70. HEBERT AA, WARKEN KA, CHERILL R: Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin. Cutan. Med. Surg. (2001) 20(4):260-267. (Pubitemid 33139093)
71. BERGBRANT IM, FAERGEMANN J: The role of Pityrosporum ovale in seborrheic dermatitis. Semin. Dermatol. (1990) 9:262-268.
72. NAKAGAWA H, ETOH T, YOKOTA T et al.: Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin. Drug Invest. (1996) 12:245-250.
73. LING MR: Topical tacrolimus and pimecrolimus: future directions. Semin. Cutan. Med. Surg. (2001) 20(4):268-274. (Pubitemid 33139094)
74. NO AUTHORS LISTED: European FK506 multi-centre Psoriasis Study Group: systemic tacrolimus is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol. (1996) 132:419-423.
75. NARWANI R, REDDY V, WINGARD J et al.: Topical tacrolimus may be useful on skin manifestations of acute and chronic graft-versus-host disease after bone marrow transplantation. Blood (1999) 94:370b(Suppl. 1). Abstract.